<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164578</url>
  </required_header>
  <id_info>
    <org_study_id>MicroVasc-DIVA</org_study_id>
    <nct_id>NCT02164578</nct_id>
  </id_info>
  <brief_title>Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease</brief_title>
  <acronym>MicroVasc-DIVA</acronym>
  <official_title>Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardovascular Risk and Subclinical Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to&#xD;
      low dose aspirin in type 2 diabetic patients.&#xD;
&#xD;
      Especially patients with cardiovascular disease and subclinical inflammation are in the focus&#xD;
      of interest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 12, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>20 weeks</time_frame>
    <description>Difference of change of forearm blood flow with venous occlusion plethysmography at baseline and after forearm ischemia after 20 weeks treatment between rivaroxaban and aspirin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laserdopplerfluxmetry (LDF)</measure>
    <time_frame>20 weeks and EOT after 52 weeks (EOT Extension)</time_frame>
    <description>change of peripheral skin microcirculatory function (measured by laserdopplerfluxmetry; LDF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulsve wave velocity / augmentation index</measure>
    <time_frame>20 weeks</time_frame>
    <description>Measurement of arterial stiffness measured by Mobilograph (IEM Inc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite laboratory measurement</measure>
    <time_frame>20 weeks and EOT after 52 weeks (EOT Extension)</time_frame>
    <description>composit laboratory markers for endothelial function,&#xD;
composite of biomarkers of inflammation&#xD;
bleeding side effects&#xD;
composite laboratory metabolic marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>EOT after 52 weeks (EOT Extension)</time_frame>
    <description>Measurement of change of maximal post-ischemic forearm blood flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Type 2 Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive IMP in 5mg b.i.d. for 20 weeks&#xD;
+ addidional 32 weeks (extension study for 80 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive IMP in a dosage of 100mg once daily for 20 weeks. Thereof 80 patients receive treatment for addidional 32 weeks (extension study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes duration between 2 and 20 years&#xD;
&#xD;
          -  Two or more components of metabolic syndrome:&#xD;
&#xD;
               -  HDL-cholesterol &lt; 1.0 mmol/L (in males) or &lt; 1.3 mmol/L (in females)&#xD;
&#xD;
               -  Elevated triglycerides (&gt; 1.7 mmol/L)&#xD;
&#xD;
               -  Elevated blood pressure (&gt; 130 mmHg systolic and/or &gt;85 mmHg diastolic or&#xD;
                  antihypertensive treatment)&#xD;
&#xD;
               -  Elevated waist circumference (&gt; 102 cm in males, &gt; 85 cm in females)&#xD;
&#xD;
          -  Or at least one of the following&#xD;
&#xD;
               -  Carotid ultrasound showing an IMT &gt; 1 mm and plaque of carotid artery or&#xD;
&#xD;
               -  Left ventricular hypertrophy or&#xD;
&#xD;
               -  Increased UACR in the absence of other renal diseases than diabetic nephropathy&#xD;
&#xD;
          -  Increased hsCRP (&gt; 2 mg/l but &lt; 10 mg/l) at or within 6 months prior to screening&#xD;
             and/or increased PAI 1 (&gt; 15 ng/ml) at or within 6 months prior to screening (the&#xD;
             historical hsCRP or PAI 1 value can be used only if the patient was in stable&#xD;
             conditions regarding the concomitant diseases and statin therapy since the time point&#xD;
             of measurement)&#xD;
&#xD;
          -  Stable treatment with statins (if tolerated/clinically indicated)&#xD;
&#xD;
          -  Age 40 - 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major cardiovascular (CV) event with need for oral anticoagulation or platelet&#xD;
             inhibitor therapy or acute coronary syndrome &lt; 12 month before study entry&#xD;
&#xD;
          -  Sustained uncontrolled hypertension: systolic blood pressure &gt; 180 mmHg or diastolic&#xD;
             blood pressure &gt; 100 mmHg&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients&#xD;
&#xD;
          -  Active clinically significant bleeding&#xD;
&#xD;
          -  Lesion or condition, if considered to be a significant risk for major bleeding&#xD;
&#xD;
          -  Concomitant treatment of acute coronary syndrome (ACS) with antiplatelet therapy in&#xD;
             patients with a prior stroke or a transient ischemic attack (TIA)&#xD;
&#xD;
          -  Hepatic disease associated with coagulopathy and clinically relevant bleeding risk&#xD;
             including cirrhotic patients with Child Pugh B and C&#xD;
&#xD;
          -  Chronic renal failure with eGFR &lt; 15 ml/min (MDRD formula)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman and woman without adequate method of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Pistrosch, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GWT-TUD GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin / Charité Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Schaper/ Dr. Faulmann</name>
      <address>
        <city>Dresden</city>
        <zip>01279</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH / Studienzentrum Hanefeld</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologicum Prina</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 26, 2021</submitted>
    <returned>March 22, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

